about
Linkers Having a Crucial Role in Antibody-Drug ConjugatesPreclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationChallenges in Antibody Development against Tn and Sialyl-Tn AntigensAntibody-drug conjugates as novel anti-cancer chemotherapeuticsRibosome-inactivating proteins: from plant defense to tumor attackNanotheranostics for personalized medicineCurrent Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisChallenges and advances in the assessment of the disposition of antibody-drug conjugatesAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsNew Dioxaborolane Chemistry Enables [(18)F]-Positron-Emitting, Fluorescent [(18)F]-Multimodality Biomolecule Generation from the Solid PhaseTargeted delivery of chemotherapy agents using a liver cancer-specific aptamerDOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7aglA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaDevelopment and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic CancerChemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug ConjugatesProtease-Sensitive Nanomaterials for Cancer Therapeutics and Imaging.Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detectionNext generation of antibody therapy for cancer.Molecularly defined antibody conjugation through a selenocysteine interface.Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments.Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.A rapid, site-selective and efficient route to the dual modification of DARPins.Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy.A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.Trends in cancer immunotherapyChemical glycosylation of cytochrome c improves physical and chemical protein stability.Photochemical internalization of tumor-targeted protein toxins.Improving the serum stability of site-specific antibody conjugates with sulfone linkers.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesModified bleomycin disaccharides exhibiting improved tumor cell targetingInitial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.Design, Synthesis and Application of Fluorine-Labeled Taxoids as (19)F NMR Probes for the Metabolic Stability Assessment of Tumor-Targeted Drug Delivery Systems.Application of a water-soluble pyridyl disulfide amine linker for use in Cu-free click bioconjugation.Site-specific modification of ED-B-targeting antibody using intein-fusion technology.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Oligoclonal antibodies to target the ErbB family.N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two ProteinsMultiple site-specific in vitro labeling of single-chain antibodyTargeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.
P2860
Q26752763-D1C48EB4-2162-421D-A5F0-AD079A1C8F32Q26784048-75E1F231-A292-4F6F-81EF-C325547DA11BQ26798183-D53155F3-BDB6-4101-8EB9-A16861C2E0B2Q26800175-BEB66ECD-5703-4E52-9B8D-C0A0E0A5A972Q26828935-D163C6E3-0FC6-44EF-9411-82449E9EF774Q26851449-50D6A873-AF7A-4C6C-AE4A-25627B39D094Q28077780-BA861833-E6FF-4F5B-80D3-4CBE0B472083Q28085074-C8EBDBDC-8A2F-4CEB-AA1E-35BA5223C17CQ28270261-519745E1-25D4-4170-A0E6-4D45595C286CQ28274697-F02A76F6-4C49-474E-9E4C-9311A389CC9FQ28482911-DCFC8F9D-B1E8-40A1-8DE6-AF580E1D12F6Q28485909-654203BB-D593-4034-B5C3-A3AC971567DFQ28487973-50D49305-53ED-47E5-90A2-FB71E0F22AE6Q28552050-A471CFC2-BC01-4284-B3C3-7FC429F1F5F3Q28828981-086536B2-CB36-4DC3-A4AB-65B237DAD78EQ30355600-CE4493C9-53FA-4F33-A276-7B94500297EEQ33441587-C759A371-5449-4B38-A7FD-A718CBD96107Q33579636-9F6B0911-193C-4755-A1E1-980F8D87B846Q33675575-E3EF824C-A97B-4E93-B26C-F88123CF82A2Q33763294-79DD925A-FC83-4C5D-BBE8-23866594EDFEQ33845533-7FA9D8FB-6562-44BF-9355-ADFBD8D24920Q33879313-48A709C8-2594-4AAB-8E48-7F634AFE67D5Q33894592-C1296B00-A82B-4F2C-A9BD-7F1583C6BACDQ34009357-9E5D6B8A-9A5F-4330-81DF-36E2F491A428Q34052702-20F876FD-4FAF-4CD0-8F5D-CF2DA9DDE910Q34062756-A4773080-1E41-4CD0-884E-6F570320BD8EQ34068201-268F7250-F8C2-4657-A1ED-87EAE965897AQ34074771-1EA0A070-AAD2-408D-B6E4-008452FC6D70Q34293689-0782E2A5-EBE9-439B-ACF5-2EF82CF9DCFBQ34463923-036CDE88-737A-4546-AA41-4C41F619B907Q34792334-7D65DA4E-63F3-463D-BC77-EE6A1ADA93B8Q35110101-87CB5109-5197-48CC-A812-5535584CE727Q35148819-84A61BD4-9D99-463F-AC4F-C8D069B26297Q35158352-5BCAF2AB-D069-4890-B4FA-379DFED5FF29Q35569418-F15AEA20-25DD-4124-AEA1-548E84C3AA8FQ35780145-A97B7A85-D8CC-4F63-BE35-5D5233640DBEQ35924212-C45634BC-5173-4806-89F3-EECA5418EF54Q36081864-6F6AAA4C-A2A3-408F-A701-5178E00A4B27Q36108943-C8D06C38-412C-4F90-BEC5-3F761675966BQ36142511-B7F13CFA-958B-4598-BF5B-805CC399ADB6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibody-drug conjugates for cancer therapy.
@en
Antibody-drug conjugates for cancer therapy.
@nl
type
label
Antibody-drug conjugates for cancer therapy.
@en
Antibody-drug conjugates for cancer therapy.
@nl
prefLabel
Antibody-drug conjugates for cancer therapy.
@en
Antibody-drug conjugates for cancer therapy.
@nl
P1433
P1476
Antibody-drug conjugates for cancer therapy.
@en
P2093
Paul J Carter
Peter D Senter
P304
P356
10.1097/PPO.0B013E318172D704
P577
2008-05-01T00:00:00Z